Donnerstag, 2. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE
MAHOGANY

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Rekrutierend

NCT-Nummer:
NCT05100862

Studienbeginn:
März 2022

Letztes Update:
24.04.2024

Wirkstoff:
Zanubrutinib, Rituximab, Lenalidomide, Obinutuzumab

Indikation (Clinical Trials):
Lymphoma, Lymphoma, B-Cell, Marginal Zone

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
BeiGene

Collaborator:
-

Studienleiter

Study Director
Study Director
BeiGene
Study Director
Principal Investigator
BeiGene

Kontakt

Studienlocations
(3 von 171)

Kaiser Permanente Southern California
92618 Irvine
United StatesRekrutierend» Google-Maps
Los Angeles Cancer Network
90017 Los Angeles
United StatesRekrutierend» Google-Maps
Valkyrie Clinical Trials
90067 Los Angeles
United StatesRekrutierend» Google-Maps
Baptist Md Anderson Cancer Center
32207 Jacksonville
United StatesRekrutierend» Google-Maps
Ascension Sacred Heart
32504 Pensacola
United StatesRekrutierend» Google-Maps
Northwest Georgia Oncology Centers Marietta
30060 Marietta
United StatesRekrutierend» Google-Maps
Fort Wayne Medical Oncology and Hematology
46804 Fort Wayne
United StatesRekrutierend» Google-Maps
Mission Cancer and Blood
50309 Des Moines
United StatesRekrutierend» Google-Maps
Cotton Oneil Cancer Center
66606 Topeka
United StatesRekrutierend» Google-Maps
University of Maryland Greenebaum Comprehensive Cancer Center
21201 Baltimore
United StatesRekrutierend» Google-Maps
American Oncology Partners of Maryland Pa
20817 Bethesda
United StatesRekrutierend» Google-Maps
Hattiesburg Hematology and Oncology Clinic
39401 Hattiesburg
United StatesRekrutierend» Google-Maps
University of Missouri Hospital, Ellis Fischel Cancer Center
65212 Columbia
United StatesRekrutierend» Google-Maps
Oncology Hematology Associates
65807 Springfield
United StatesRekrutierend» Google-Maps
St Vincent Frontier Cancer Center
59102 Billings
United StatesRekrutierend» Google-Maps
Nebraska Cancer Specialists (Satellite Site)
68803 Grand Island
United StatesRekrutierend» Google-Maps
Nebraska Cancer Specialists
68803 Grand Island
United StatesRekrutierend» Google-Maps
Summit Medical Group
07932 Florham Park
United StatesRekrutierend» Google-Maps
Clinical Research Alliance, Inc
11590 Westbury
United StatesRekrutierend» Google-Maps
Va Northeast Ohio Healthcare System
44106 Cleveland
United StatesRekrutierend» Google-Maps
Toledo Clinic Cancer Center
43623 Toledo
United StatesRekrutierend» Google-Maps
Mainline Health Lankenau Institute For Medical Research
19096 Wynnewood
United StatesRekrutierend» Google-Maps
Cancer Care Associates of York
17403 York
United StatesRekrutierend» Google-Maps
Prairie Lakes Healthcare System
57201 Watertown
United StatesRekrutierend» Google-Maps
Texas Oncology Baylorcharles A Sammons Cancer Center
75246 Dallas
United StatesRekrutierend» Google-Maps
Md Anderson Cancer Center
77030 Houston
United StatesRekrutierend» Google-Maps
Medical Oncology Associates
99208 Spokane
United StatesRekrutierend» Google-Maps
Hospital Italiano de Buenos Aires
C1199ABB Buenos Aires
ArgentinaRekrutierend» Google-Maps
Concord Repatriation General Hospital
2139 Concord
AustraliaRekrutierend» Google-Maps
Port Macquarie Base Hospital
2444 Port Macquarie
AustraliaRekrutierend» Google-Maps
Sunshine Coast Hospital and Health Service
4575 Birtinya
AustraliaRekrutierend» Google-Maps
Townsville University Hospital
4814 Douglas
AustraliaRekrutierend» Google-Maps
St Vincents Hospital Melbourne
3065 Fitzroy
AustraliaRekrutierend» Google-Maps
La Trobe Regional Hospital
3844 Melbourne
AustraliaRekrutierend» Google-Maps
Hospital de Amor Barretos
14784-400 Barretos
BrazilRekrutierend» Google-Maps
Clinica de Oncologia Reichow
89010-340 Blumenau
BrazilRekrutierend» Google-Maps
Unesp Faculdade de Medicina Da Universidade Estadual Paulista Campus Botucatu
18618687 Botucatu
BrazilRekrutierend» Google-Maps
Instituto Dor de Pesquisa E Ensino Distrito Federal
70390140 Brasilia
BrazilRekrutierend» Google-Maps
Universidade de Campinas Centro de Hematologia E Hemoterapia
13083-878 Campinas
BrazilRekrutierend» Google-Maps
Fundacao Universidade de Caxias Do Sul
95070-560 Caxias do Sul
BrazilRekrutierend» Google-Maps
Centro Integrado de Oncologia de Curitiba Ss Cionc
80810-050 Curitiba
BrazilRekrutierend» Google-Maps
Hospital Erasto Gaertner
81520-060 Curitiba
BrazilRekrutierend» Google-Maps
Centro de Ensino E Pesquisa Em Oncologia de Santa Catarina (Cepen)
88020-210 Florianopolis
BrazilRekrutierend» Google-Maps
Hospital Ernesto Dornelles
90160-093 Porto Alegre
BrazilRekrutierend» Google-Maps
Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
90850-170 Porto Alegre
BrazilRekrutierend» Google-Maps
Instituto Dor de Pesquisa E Ensino
50070170 Recife
BrazilRekrutierend» Google-Maps
Hospital Das Clinicas Da Faculdade de Medicina de Ribeirao Preto Usp
14051-140 Ribeirao Preto
BrazilRekrutierend» Google-Maps
Oncoclinicas Rio de Janeiro Sa
22250-905 Rio de Janeiro
BrazilRekrutierend» Google-Maps
Instituto Americas Ensino, Pesquisa E Inovacao
22775-001 Rio de Janeiro
BrazilRekrutierend» Google-Maps
Complexo Hospitalar de Niteroi
24020-096 Rio de Janeiro
BrazilRekrutierend» Google-Maps
Ensino E Terapia de Inovacao Clinica Amo Etica
41950640 Salvador
BrazilRekrutierend» Google-Maps
Instituto Dor de Pesquisa E Ensino Sao Paulo
01401-002 Sao Paulo
BrazilRekrutierend» Google-Maps
Hospital Nove de Julho Dasa
01409-902 Sao Paulo
BrazilRekrutierend» Google-Maps
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
05653-120 Sao Paulo
BrazilRekrutierend» Google-Maps
Hospital Santa Rita de Cassia Afecc
29043260 Vitoria
BrazilRekrutierend» Google-Maps
The First Affiliated Hospital of Wannan Medical College
241001 Wuhu
ChinaRekrutierend» Google-Maps
Beijing Friendship Hospital, Capital Medical University
100050 Beijing
ChinaRekrutierend» Google-Maps
Sun Yat Sen University Cancer Center
510060 Guangzhou
ChinaRekrutierend» Google-Maps
Huizhou Central Peoples Hospital
516001 Huizhou
ChinaRekrutierend» Google-Maps
Affiliated Hospital of Guangdong Medical University
524000 Zhanjiang
ChinaRekrutierend» Google-Maps
Harbin Medical University Cancer Hospital
150000 Harbin
ChinaRekrutierend» Google-Maps
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
430022 Wuhan
ChinaRekrutierend» Google-Maps
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
430030 Wuhan
ChinaRekrutierend» Google-Maps
The First Peoples Hospital of Changde City
415000 Changde
ChinaRekrutierend» Google-Maps
Affiliated Hospital of Nantong University
201203 Nantong
ChinaRekrutierend» Google-Maps
The First Affiliated Hospital of Soochow University
215006 Suzhou
ChinaRekrutierend» Google-Maps
Jiangxi Province Cancer Hospital
330029 Nanchang
ChinaRekrutierend» Google-Maps
The First Affiliated Hospital of Nanchang University Branch Xianghu
332000 Nanchang
ChinaRekrutierend» Google-Maps
The First Hospital of Jilin University
130021 Changchun
ChinaRekrutierend» Google-Maps
Shengjing Hospital of China Medical University
110004 Shenyang
ChinaRekrutierend» Google-Maps
The Second Affiliated Hospital of Shandong First Medical University
271099 Taian
ChinaRekrutierend» Google-Maps
Shanxi Provincial Cancer Hospital
030013 Taiyuan
ChinaRekrutierend» Google-Maps
West China Hospital, Sichuan University
610041 Chengdu
ChinaRekrutierend» Google-Maps
The First Hospital of Jiaxing
314001 Jiaxing
ChinaRekrutierend» Google-Maps
Jinhua Municipal Central Hospital
321000 Jinhua
ChinaRekrutierend» Google-Maps
The First Affiliated Hospital of Wenzhou Medical University
325000 Wenzhou
ChinaRekrutierend» Google-Maps
Fakultni Nemocnice Hradec Kralove
50005 Hradec Kralove
CzechiaRekrutierend» Google-Maps
Hopital Prive Dantony, Departement Dhemathologie
92160 Antony
FranceRekrutierend» Google-Maps
Chu Montpellier Hopital Saint Eloi
34295 Montpellier Cedex
FranceRekrutierend» Google-Maps
Icans Institut de Cancerologie Strasbourg Europe
67033 Strasbourg
FranceRekrutierend» Google-Maps
Centre Hospitalier Universitaire de Nancy Hopital de Brabois
54511 VandoeuvrelesNancy
FranceRekrutierend» Google-Maps
University Hospital Waterford
X91 ER8E Waterford
IrelandRekrutierend» Google-Maps
Assuta Ashdod Medical Center
7747629 Ashdod
IsraelRekrutierend» Google-Maps
Shaare Zedek Medical Center
9103102 Jerusalem
IsraelRekrutierend» Google-Maps
Hadassah En Karem Medical Center
9112001 Jerusalem
IsraelRekrutierend» Google-Maps
Chaim Sheba Medical Center
5265601 Ramat gan
IsraelRekrutierend» Google-Maps
Irccs Azienda Ospedaliero Universitaria Bologna
40138 Bologna
ItalyRekrutierend» Google-Maps
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
20162 Milano
ItalyRekrutierend» Google-Maps
Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
27100 Pavia
ItalyRekrutierend» Google-Maps
Arcispedale S Maria Nuova Ausl Reggio Emilia Hematology Unit
42123 Reggio Emilia
ItalyRekrutierend» Google-Maps
Aou Santa Maria Della Misericordia Di Udine
33100 Udine
ItalyRekrutierend» Google-Maps
Ospedale Di Circolo E Fondazione Macchi
21100 Varese
ItalyRekrutierend» Google-Maps
Inje University Busan Paik Hospital
47392 Busan
Korea, Republic ofRekrutierend» Google-Maps
Dong A University Hospital
49201 Busan
Korea, Republic ofRekrutierend» Google-Maps
Pusan National University Hospital
49241 Busan
Korea, Republic ofRekrutierend» Google-Maps
Seoul National University Bundang Hospital
13620 Seongnamsi
Korea, Republic ofRekrutierend» Google-Maps
Korea University Anam Hospital
02841 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Kyungpook National University Chilgok Hospital
41404 Daegu
Korea, Republic ofRekrutierend» Google-Maps
Gyeongsang National University Hospital
52727 Jinjusi
Korea, Republic ofRekrutierend» Google-Maps
Chonnam National University Hwasun Hospital
58128 Hwasungun
Korea, Republic ofRekrutierend» Google-Maps
Seoul National University Hospital
03080 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Severance Hospital Yonsei University Health System
03722 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Soon Chun Hyang University Hospital Seoul
04401 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Asan Medical Center
05505 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Samsung Medical Center
06351 Seoul
Korea, Republic ofRekrutierend» Google-Maps
The Catholic University of Korea, Seoul St Marys Hospital
06591 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Pan American Oncology Trials, Llc
00935 Rio Piedras
Puerto RicoRekrutierend» Google-Maps
Auxilio Mutuo Cancer Center
00917 San Juan
Puerto RicoRekrutierend» Google-Maps
Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca
400015 ClujNapoca
RomaniaRekrutierend» Google-Maps
Institutul Regional de Oncologie Iasi
700483 Iasi
RomaniaRekrutierend» Google-Maps
Spitalul Clinic Judetean de Urgenta Bihor
410469 Oradea
RomaniaRekrutierend» Google-Maps
Hospital Universitario de Burgos
09006 Burgos
SpainRekrutierend» Google-Maps
Hospital Universitario Puerta Del Mar
11009 Cadiz
SpainRekrutierend» Google-Maps
Hospital Universitario Virgen de Las Nieves
18014 Granada
SpainRekrutierend» Google-Maps
Institut Catala Doncologia Hospital Duran I Reynals
8908 Hospitalet de LLobregat
SpainRekrutierend» Google-Maps
Complejo Asistencial Universitario de Leon
24071 Leon
SpainRekrutierend» Google-Maps
Hospital Universitario Infanta Leonor
28031 Madrid
SpainRekrutierend» Google-Maps
Hospital Universitario Ramon Y Cajal
28034 Madrid
SpainRekrutierend» Google-Maps
Hospital Clinico Universitario Virgen de La Arrixaca
30120 Murcia
SpainRekrutierend» Google-Maps
Clinica Universidad de Navarra Pamplona
31008 Pamplona
SpainRekrutierend» Google-Maps
Hospital Universitario Quironsalud Madrid
28223 Pozuelo de Alarcon
SpainRekrutierend» Google-Maps
Hospital Universitario de Salamanca
37007 Salamanca
SpainRekrutierend» Google-Maps
Hospital Universitario Virgen Del Rocio
41013 Sevilla
SpainRekrutierend» Google-Maps
Hospital Universitari Mutua Terrassa
8221 Terassa
SpainRekrutierend» Google-Maps
Beatson West of Scotland Cancer Centre
G12 0YN Glasgow
United KingdomRekrutierend» Google-Maps
The Christie Hospital
M20 4BX Greater Manchester
United KingdomRekrutierend» Google-Maps
Huddersfield Royal Infirmary
HD3 3EA Huddersfield
United KingdomRekrutierend» Google-Maps
The Leeds Teaching Hospitals Nhs Trust
LS9 7TF Leeds
United KingdomRekrutierend» Google-Maps
University College Hospital
NW1 2PG London
United KingdomRekrutierend» Google-Maps
Derriford Hospital
PL6 8DH Plymouth
United KingdomRekrutierend» Google-Maps
Southampton General Hospital
SO16 6YD Southampton
United KingdomRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus

lenalidomide plus rituximab (R^2) in participants with relapsed/refractory (R/R) follicular

lymphoma (FL), as measured by progression-free survival as determined by an independent

review committee in accordance with the 2014 modification of the International Working Group

on non-Hodgkin lymphoma (NHL) Criteria based on n positron emission tomography and computed

tomography (PET/CT), and to compare the efficacy of zanubrutinib plus rituximab versus R^2 in

participants with R/R marginal zone lymphoma (MZL), as measured by progression free survival

(PFS) assessed by IRC in accordance with CT-based Lugano 2014 Criteria.

Ein-/Ausschlusskriterien

Key Inclusion Criteria:

- Histologically confirmed grade 1-3a FL or MZL

- Previously treated with ≥ 1 line of systemic therapy including anti-CD20 agent. Must

have a documented failure to achieve at least partial response during the most recent

systemic therapy or documented progressive disease after the most recent systemic

therapy

- Need for systemic therapy for FL or MZL

- Measurable disease by computed tomography or magnetic resonance imaging

- Adequate bone marrow, liver and renal function

Key Exclusion Criteria:

- Transformation to aggressive lymphoma

- Requiring ongoing need for corticosteroid treatment

- Clinically significant cardiovascular disease

- Prior malignancy within the past 2 years

- Active fungal, bacterial, and/or viral infection that requires systemic therapy

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Studien-Rationale

Primary outcome:

1. Progression-free Survival As Determined By A Blinded Independent Review Committee (BIRC) (Time Frame - Approximately 78 months)



Secondary outcome:

1. Progression-free Survival As Determined By Investigator Assessment (Time Frame - Approximately 87 months)

2. Duration Of Response As Determined By BIRC And By Investigator Assessment (Time Frame - Approximately 87 months)

3. Overall Response Rate As Determined By BIRC And By Investigator Assessment (Time Frame - Approximately 87 months)

4. Complete Response Rate As Determined By BIRC And By Investigator Assessment (Time Frame - Approximately 87 months)

5. Time To Response As Determined By BIRC And By Investigator Assessment (Time Frame - Approximately 87 months)

6. Time to Next Ant-Lymphoma Treatment (Time Frame - Approximately 87 months)

7. Overall Survival (Time Frame - Approximately 87 months)

8. Health-related Quality Of Life (HRQoL) Using EORTC QLQ-C30) (Time Frame - Approximately 87 months):
HRQ0L assessed by The European Organization For Research On Treatment Of Cancer Quality Of Life Questionnaire-core 30 (EORTC QLQ-C30) consists of 30 questions that are associated with 5 functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, pain, and nausea and vomiting), and 6 single symptom items ( dyspnoea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The scores range from 0 to 100 and higher score indicates better quality of life.

9. HRQoL Using European Quality of Life 5 Dimension 5 Level Questionnaire [EQ 5D 5L) (Time Frame - Approximately 87 months):
The EQ-5D-5L is comprised of a descriptive module and a visual analogue scale. The EQ-5D-5L descriptive module comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The visual analogue scale records the respondent's self-rated health on a 0 to 100 scale, with 100 labeled "the best health you can imagine" and 0 labeled "the worst health you can imagine. Higher scores indicate better quality of life.

10. HRQoL Using National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Symptom Index-18 [FLymSI 18) (Time Frame - Approximately 87 months):
The FLymSI-18 is comprised of 18 questions which cover 4 sub-scales: physical symptoms, emotional symptoms, side effects, and functional well-being. Scores are based on the 5-level Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and is divided into a total score. Higher score indicates better quality of life.

11. Number of Participants Experiencing Adverse Events (AEs) (Time Frame - From first dose to 28 days after the last dose of zanubrutinib or lenalidomide, 90 days after the last dose of obinutuzumab or rituximab, or until the date of confirmed disease progression, whichever comes later (Approximately 87 months))

Studien-Arme

  • Experimental: Follicular Lymphoma Arm A: Zanubrutinib plus Obinutuzumab
    Participants will receive zanubrutinib and Obinutuzumab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.
  • Active Comparator: Follicular Lymphoma Arm B: Lenalidomide plus Rituximab
    Participants will receive lenalidomide and rituximab.
  • Experimental: Marginal Zone Lymphoma Arm C: Zanubrutinib plus Rituximab
    Participants will receive zanubrutinib and rituximab. Following the completion of the combination treatment, participants will continue receiving zanubrutinib monotherapy until confirmed disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.
  • Active Comparator: Marginal Zone Lymphoma Arm D: Lenalidomide plus Rituximab
    Participants will receive lenalidomide and rituximab.

Geprüfte Regime

  • Zanubrutinib (BGB-3111 / Brukinsa / ):
    Zanubrutinib will be administered orally as two 80-milligram (mg) capsules twice a day (160 mg twice a day) or four 80-mg capsules once a day (320 mg once a day) continuously in repeated 28-day cycles.
  • Rituximab (Rituxan / MabThera / Ruxience / Truxima / ):
    Rituximab will be administered intravenously at a dose of 375 mg/meter squared on Days 1, 8, 15, and 22 of Cycle 1 and on Day 1 of Cycles 2 to 5. Each cycle is 28 days in length.
  • Lenalidomide (Revlimid):
    Lenalidomide will be administered orally as 20-mg capsules (10 mg if creatinine clearance ≥ 30 mL/min but < 60 mL/min) once a day on Days 1 to 21 of each 28-day cycle for a total of 12 cycles.
  • Obinutuzumab:
    Obinutuzumab will be administered at a dose of 1000 mg on Cycle 1 Days 1, 8, 15 and then on Cycles 2 to 6 Day 1.

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.